Literature DB >> 3755711

Analogues of RSU-1069: radiosensitization and toxicity in vitro and in vivo.

I Ahmed, T C Jenkins, J M Walling, I J Stratford, P W Sheldon, G E Adams, E M Fielden.   

Abstract

A series of nitroimidazoles containing aziridine and alkyl-substituted aziridine functions has been synthesized. The 2-nitroimidazole compounds examined all show greater radiosensitizing efficiency in vitro than misonidazole. The 4- and 5-nitroimidazole analogues are also more efficient than equivalent compounds which do not contain the alkylating aziridine moiety. All the compounds show increased toxicity towards hypoxic cells relative to aerobic cells, but this toxicity is reduced by alkyl-substitution of the aziridine ring. In vivo toxicity can also be reduced by modification of the aziridine function, but such alterations appear to have less effect upon the high radiosensitizing efficiency of these compounds in vivo. As a consequence of this study, compounds of potentially improved therapeutic utility compared to RSU-1069, the first reported member of this class, have been identified.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755711     DOI: 10.1016/0360-3016(86)90230-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.

Authors:  M I Walton; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 2.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

3.  High uptake of RSU 1069 and its analogues melanotic melanomas.

Authors:  J M Walling; J Deacon; S Holliday; I J Stratford
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.

Authors:  K H Wong; C J Koch; C A Wallen; K T Wheeler
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

5.  Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.

Authors:  L M Cobb; J Nolan; S A Butler
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

6.  Synthesis, in vitro aerobic and hypoxic cytotoxicity and radiosensitizing activity of novel metronidazole tethered 5-fluorouracil.

Authors:  Khosrou Abdi; Ali Khalaj; Seyed Nasser Ostad; Navid Lamei; Mohammad Reza Khoshayand
Journal:  Daru       Date:  2013-12-20       Impact factor: 3.117

7.  Cytotoxicity and radiosensitising activity of synthesized dinitrophenyl derivatives of 5-fluorouracil.

Authors:  Khosrou Abdi; Ali Khalaj; Syeed-Naser Ostad; Mohammad Reza Khoshayand
Journal:  Daru       Date:  2012-07-19       Impact factor: 3.117

8.  Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.

Authors:  J C Bremner; G E Adams; J K Pearson; J M Sansom; I J Stratford; J Bedwell; S G Bown; A J MacRobert; D Phillips
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

9.  E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications.

Authors:  Alexandra Marie Mowday; Janine Naomi Copp; Sophie Philippa Syddall; Ludwig Jerome Dubois; Jingli Wang; Natasja Gabi Lieuwes; Rianne Biemans; Amir Ashoorzadeh; Maria Rosaria Abbattista; Elsie May Williams; Christopher Paul Guise; Philippe Lambin; David Francis Ackerley; Jeff Bruce Smaill; Jan Theys; Adam Vorn Patterson
Journal:  Theranostics       Date:  2020-08-21       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.